Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector
- PMID: 7504271
- PMCID: PMC47827
- DOI: 10.1073/pnas.90.22.10613
Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector
Abstract
Adeno-associated virus (AAV) vectors expressing the normal cystic fibrosis transmembrane conductance regulator (CFTR) cDNA complement the cystic fibrosis (CF) defect in vitro. Unlike other DNA virus vectors, AAV is a stably integrating virus, which could make possible long-term in vivo complementation of the CF defect in the airway epithelium. We report AAV-CFTR gene transfer and expression after infection of primary CF nasal polyp cells and after in vivo delivery of AAV-CFTR vector to one lobe of the rabbit lung through a fiberoptic bronchoscope. In the rabbit, vector DNA could be detected in the infected lobe up to 6 months after administration. A 26-amino acid polypeptide sequence unique to the recombinant AAV-CFTR protein was used to generate both oligonucleotide probes and a polyclonal antibody which allowed the unambiguous identification of vector RNA and CFTR protein expression. With these reagents, CFTR RNA and protein were detected in the airway epithelium of the infected lobe for up to 6 months after vector administration. AAV vectors do, therefore, efficiently promote in vivo gene transfer to the airway epithelium which is stable over several months. These findings indicate that AAV-CFTR vectors could potentially be very useful for gene therapy.
Similar articles
-
Safety of single-dose administration of an adeno-associated virus (AAV)-CFTR vector in the primate lung.Gene Ther. 1996 Aug;3(8):658-68. Gene Ther. 1996. PMID: 8854091
-
Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter.J Biol Chem. 1993 Feb 15;268(5):3781-90. J Biol Chem. 1993. PMID: 7679117
-
Safety and biological efficacy of an adeno-associated virus vector-cystic fibrosis transmembrane regulator (AAV-CFTR) in the cystic fibrosis maxillary sinus.Laryngoscope. 1999 Feb;109(2 Pt 1):266-74. doi: 10.1097/00005537-199902000-00017. Laryngoscope. 1999. PMID: 10890777 Clinical Trial.
-
Gene therapy in cystic fibrosis.Chest. 2001 Sep;120(3 Suppl):124S-131S. doi: 10.1378/chest.120.3_suppl.124s. Chest. 2001. PMID: 11555567 Review.
-
Gene therapy for the respiratory manifestations of cystic fibrosis.Am J Respir Crit Care Med. 1995 Mar;151(3 Pt 2):S75-87. doi: 10.1164/ajrccm/151.3_Pt_2.S75. Am J Respir Crit Care Med. 1995. PMID: 7533609 Review.
Cited by
-
Cell and gene therapy for genetic diseases: inherited disorders affecting the lung and those mimicking sudden infant death syndrome.Hum Gene Ther. 2012 Jun;23(6):548-56. doi: 10.1089/hum.2012.087. Hum Gene Ther. 2012. PMID: 22642257 Free PMC article. Review.
-
Development of Novel Recombinant AAV Vectors and Strategies for the Potential Gene Therapy of Hemophilia.J Genet Syndr Gene Ther. 2012 Jan 10;S1:008. doi: 10.4172/2157-7412.S1-008. J Genet Syndr Gene Ther. 2012. PMID: 23264889 Free PMC article.
-
Pronounced Therapeutic Benefit of a Single Bidirectional AAV Vector Administered Systemically in Sandhoff Mice.Mol Ther. 2020 Oct 7;28(10):2150-2160. doi: 10.1016/j.ymthe.2020.06.021. Epub 2020 Jun 19. Mol Ther. 2020. PMID: 32592687 Free PMC article.
-
Recombinant adeno-associated viral (rAAV) vectors mediate efficient gene transduction in cultured neonatal and adult microglia.J Neurochem. 2016 Jan;136 Suppl 1(0 1):49-62. doi: 10.1111/jnc.13081. Epub 2015 Mar 20. J Neurochem. 2016. PMID: 25708596 Free PMC article.
-
Intranasal vaccination with recombinant adeno-associated virus type 5 against human papillomavirus type 16 L1.J Virol. 2006 Mar;80(6):2621-30. doi: 10.1128/JVI.80.6.2621-2630.2006. J Virol. 2006. PMID: 16501072 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical